Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease

• Published in: Journal of the American College of Cardiology Vol. 64; no. 10; pp. 1005 - 1014
• Main Authors: Angiolillo, Dominick J., Jakubowski, Joseph A., Ferreiro, José Luis, Tello-Montoliu, Antonio, Rollini, Fabiana, Franchi, Francesco, Ueno, Masafumi, Darlington, Andrew, Desai, Bhaloo, Moser, Brian A., Sugidachi, Atsuhiro, Guzman, Luis A., Bass, Theodore A.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 09.09.2014; Elsevier
• Subjects: Adult; Aged; Aspirin - adverse effects; Aspirin - therapeutic use; Biological and medical sciences; Cardiology. Vascular system; Cohort Studies; Coronary Artery Disease - blood; Coronary Artery Disease - complications; Coronary Artery Disease - drug therapy; coronary disease; Coronary heart disease; diabetes mellitus; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes. Impaired glucose tolerance; Dose-Response Relationship, Drug; Drug Administration Schedule; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Follow-Up Studies; Heart; Humans; Male; Medical sciences; Middle Aged; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Platelet Function Tests; platelets; Prospective Studies; Purinergic P2Y Receptor Antagonists - adverse effects; Purinergic P2Y Receptor Antagonists - therapeutic use; Reference Values; Risk Assessment; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use; Treatment Outcome; PRI; DM; diabetes mellitus; ADP; PRP; coronary disease; ANCOVA; MFI; PRU; CYP; VASP; Cmax; AUC[0-tlast]; PGE1; CAD; LSM; platelets; VASP-P; ACS; Clop-AM; PD; LD; LTA; VN; PK; Endocrinopathy; Type 2 diabetes; Human; Metabolic diseases; Patient; Cardiovascular disease; Coronary heart disease; Antiplatelet agent; Platelet; Antithrombotic agent; Clopidogrel; Antagonist; Circulatory system; Thienopyridine derivative; Cardiology; Biological receptor

Several studies have shown that patients with diabetes mellitus (DM) exhibit an impaired response to clopidogrel. This may contribute to their increased risk of recurrent atherothrombotic events, despite the use of dual-antiplatelet therapy. The mechanisms for impaired clopidogrel response in DM pat...